EYPT: DME Phase III results are the pivotal next catalyst after wet AMD trials missed their primary endpoint
EyePoint Inc. (EYPT) reported that its LUGANO and LUCIA trials for wet AMD did not meet the primary endpoint, but secondary results support continued development of DURAVYU. The company's fully enrolled DME Phase III trials, expected to report in early Q4 2027, are the next key catalyst, according to a UBS conference transcript.
